[{"orgOrder":0,"company":"Shaperon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taurodeoxycholic Acid","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Shaperon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/ Not Applicable"},{"orgOrder":0,"company":"Hudson Therapeutics","sponsor":"Shaperon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"Inflammasome","graph1":"Dermatology","graph2":"Phase II","graph3":"Hudson Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hudson Therapeutics \/ Shaperon","highestDevelopmentStatusID":"8","companyTruncated":"Hudson Therapeutics \/ Shaperon"}]

Find Clinical Drug Pipeline Developments & Deals for Taurodeoxycholic Acid

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : NuGel, a first-in-class topical inflammasome inhibitor, which is being evaluated for the treatment of mild to moderate atopic dermatitis.

                          Product Name : NuGel

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 10, 2025

                          Lead Product(s) : Taurodeoxycholic Acid

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Shaperon

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : NuGel® is a gel type atopic dermatitis drug candidate, inhibiting NLRP3 inflammasome through GPCR19-P2X7 modulation. Its active pharmaceutical ingredient called HY209.

                          Product Name : Nugel

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 18, 2024

                          Lead Product(s) : Taurodeoxycholic Acid

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank